ZA200903529B - Detection system and uses therefor - Google Patents

Detection system and uses therefor

Info

Publication number
ZA200903529B
ZA200903529B ZA200903529A ZA200903529A ZA200903529B ZA 200903529 B ZA200903529 B ZA 200903529B ZA 200903529 A ZA200903529 A ZA 200903529A ZA 200903529 A ZA200903529 A ZA 200903529A ZA 200903529 B ZA200903529 B ZA 200903529B
Authority
ZA
South Africa
Prior art keywords
detection system
uses therefor
therefor
detection
Prior art date
Application number
ZA200903529A
Other languages
English (en)
Inventor
Kevin Donald George Pfleger
Ruth Marie Seeber
Heng Boon See
Karin Ann Eidne
Original Assignee
Dimerix Bioscience Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006906292A external-priority patent/AU2006906292A0/en
Application filed by Dimerix Bioscience Pty Ltd filed Critical Dimerix Bioscience Pty Ltd
Publication of ZA200903529B publication Critical patent/ZA200903529B/xx

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200903529A 2006-11-10 2009-05-21 Detection system and uses therefor ZA200903529B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2006906292A AU2006906292A0 (en) 2006-11-10 Detection System and Uses Therefor

Publications (1)

Publication Number Publication Date
ZA200903529B true ZA200903529B (en) 2010-03-31

Family

ID=39364112

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200903529A ZA200903529B (en) 2006-11-10 2009-05-21 Detection system and uses therefor

Country Status (11)

Country Link
US (3) US20100234417A1 (de)
EP (3) EP2080012B1 (de)
JP (2) JP5313149B2 (de)
KR (1) KR20090083925A (de)
CN (1) CN101657715B (de)
AU (2) AU2007317204A1 (de)
CA (2) CA2669088C (de)
DK (1) DK2080012T3 (de)
IL (1) IL198639A (de)
WO (2) WO2008055313A1 (de)
ZA (1) ZA200903529B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0717416A2 (pt) 2006-09-21 2013-11-12 Prometheus Lab Inc Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo
BRPI0813583A2 (pt) * 2007-07-13 2014-12-30 Prometheus Lab Inc Métodos para selecionar um medicamento anticâncer, para identificar a resposta de um tumor pulmonar, e para prognosticar a resposta de um paciente, e, arranjo
EP2210104A4 (de) * 2007-11-01 2011-02-23 Univ Arizona State Zellfreie verfahren zum nachweis von protein-ligand-wechselwirkungen
WO2009108637A1 (en) 2008-02-25 2009-09-03 Prometheus Laboratories, Inc. Drug selection for breast cancer therapy using antibody-based arrays
JP2012521967A (ja) * 2009-03-27 2012-09-20 ディメリックス バイオサイエンス ピーティーワイ リミテッド 新規な受容体のヘテロ二量体／ヘテロオリゴマー
ES2627909T3 (es) 2009-07-15 2017-08-01 Diatech Holdings, Inc. Selección de fármacos para el tratamiento del cáncer gástrico usando matrices basadas en anticuercuerpos
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
CA2821985C (en) 2011-01-11 2019-07-09 Dimerix Bioscience Pty Ltd Combination therapy
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
KR101851425B1 (ko) 2011-09-02 2018-04-23 네스텍 소시에테아노님 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링
IE20120542A1 (en) * 2012-12-19 2014-07-02 Provost Fellows Foundation Scholars And Other Members Of Board Of The College Of The Holy And Undivi Novel TRH binding site in human CNS
KR102192554B1 (ko) 2013-03-13 2020-12-18 에스케이바이오팜 주식회사 탈력발작의 치료
JP6863897B2 (ja) 2015-01-09 2021-04-21 アダルタ・リミテッド Ｃｘｃｒ４結合分子
KR102085554B1 (ko) * 2018-02-21 2020-03-06 영남대학교 산학협력단 사카로마이세스 세레비시애의 g-단백질 연결 수용체에 대한 알파 팩터의 친화도 측정방법
CN111089971B (zh) * 2019-12-11 2021-01-15 浙江大学 一种膜电位调控下的蛋白相互作用定量检测装置

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
NL8720442A (nl) 1986-08-18 1989-04-03 Clinical Technologies Ass Afgeefsystemen voor farmacologische agentia.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5891646A (en) 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
EP1137940A4 (de) * 1998-10-23 2004-06-02 Glaxo Group Ltd Verfahren zur identifizierung von liganden von nukleären rezeptoren
DE60026603T2 (de) 1999-12-22 2007-03-01 PerkinElmer BioSignal Inc., Montréal Biolumineszenz-Resonanz-Energie-Transfer(BRET)-System mit großer spektraler Auflösung zwischen der Donator- und der Akzeptoremissionswellenlänge sowie dessen Verwendun
US6893827B1 (en) * 2000-02-07 2005-05-17 Applera Corporation Receptor function assay for G-protein coupled receptors and orphan receptors by reporter enzyme mutant complementation
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
NZ554913A (en) * 2001-12-14 2009-01-31 Targacept Inc Methods and compositions for the treatment of central nervous system disorders
FR2836475B1 (fr) * 2002-02-26 2007-02-23 Aventis Pharma Sa Procede de detection de ligands du recepteur de la leptine
DE10218785A1 (de) 2002-04-26 2003-11-13 Infineon Technologies Ag Halbleiterspeichereinrichtung und Betriebsverfahren für eine Halbleiterspeichereinrichtung
DE10230141B4 (de) * 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
JP2004093527A (ja) 2002-09-04 2004-03-25 Center For Advanced Science & Technology Incubation Ltd 蛍光共鳴エネルギー転移を用いた蛋白質の分析方法
ATE500270T1 (de) * 2003-05-20 2011-03-15 Univ Glasgow Materialien und methoden die sich auf g-protein gekoppelte rezeptor oligomere beziehen
US7049076B2 (en) * 2003-07-09 2006-05-23 Sentigen Biosciences, Inc. Method for assaying protein—protein interaction
US7488583B2 (en) 2003-09-25 2009-02-10 Odyssey Thera, Inc. Fragment complementation assays for G-protein-coupled receptors and their signaling pathways
WO2005050182A1 (en) * 2003-11-19 2005-06-02 Dimerix Biosciences Pty Ltd Resonance energy transfer assay system for multi-component detection
CN1627072A (zh) * 2003-12-11 2005-06-15 中国人民解放军军事医学科学院卫生学环境医学研究所 一种蛋白质芯片，其制备方法及用途

Also Published As

Publication number Publication date
EP2080012A1 (de) 2009-07-22
US20100021457A1 (en) 2010-01-28
WO2008055314A1 (en) 2008-05-15
CN101657715A (zh) 2010-02-24
JP2010509572A (ja) 2010-03-25
AU2007317204A1 (en) 2008-05-15
EP2078037A4 (de) 2010-01-27
WO2008055313A1 (en) 2008-05-15
IL198639A (en) 2015-01-29
US20130065253A1 (en) 2013-03-14
CN101657715B (zh) 2012-07-25
EP2080012A4 (de) 2010-01-27
AU2007317203A1 (en) 2008-05-15
US8568997B2 (en) 2013-10-29
CA2669088A1 (en) 2008-05-15
JP2010510175A (ja) 2010-04-02
US8283127B2 (en) 2012-10-09
CA2669088C (en) 2016-04-05
EP2080012B1 (de) 2013-03-20
DK2080012T3 (da) 2013-06-17
EP2078037A1 (de) 2009-07-15
CA2669185A1 (en) 2008-05-15
US20100234417A1 (en) 2010-09-16
IL198639A0 (en) 2010-02-17
KR20090083925A (ko) 2009-08-04
EP2605015A1 (de) 2013-06-19
JP5313149B2 (ja) 2013-10-09
AU2007317203B2 (en) 2010-12-16

Similar Documents

Publication Publication Date Title
IL198639A0 (en) Detection system and uses therefor
EP2097740A4 (de) Detektionssystem
EP2082186B8 (de) Objektpositions- und orientierungsdetektionssystem
EP2235561B8 (de) Detektions- und entfernungsbestimmungsverfahren und systeme
EP1974199A4 (de) Erfassungssystem
GB2443055B (en) Fraud detection system
GB0621625D0 (en) Location detection
GB0622466D0 (en) An object detection system
EP2009464A4 (de) Objektdetektionseinrichtung
EP1967137A4 (de) Positionserkennungssystem und positionserkennungsverfahren
PL2210246T3 (pl) System wykrywania zbliżeniowego
EP2181640A4 (de) System zum nachweis der position in einer probe und verfahren zum nachweis der position in einer probe
GB2441854B (en) An object detection system and method
EP2215269A4 (de) Konstruktsystem und verwendungen dafür
GB0618030D0 (en) Advisory systems and methods
GB0603664D0 (en) Enzyme detection
EP1960989A4 (de) Berührungserkennungssystem
EP2076417A4 (de) System zur erfassung des verlassens einer fahrbahn
EP1943127A4 (de) Objekterfassungssystem und -verfahren
GB0603190D0 (en) Detection system
GB0510916D0 (en) Detection system
GB0621990D0 (en) Detection
GB0618669D0 (en) Detection
EP2020167A4 (de) Generische elektromagnetisch entgegengewirkte systeme und verfahren
GB0624596D0 (en) Substance Detection System